Annual report

Period2024-01-21 → 2025-01-20

Filed2025-04-16

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 148

Metric	Value	Period	Scope	Source row
Revenue	¥237.2bn	2024-01-21 → 2025-01-20	Cons.	Net sales
Revenue	¥213.4bn	2023-01-21 → 2024-01-20	Cons.	Net sales
Revenue	¥160.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥162.6bn	2021-01-21 → 2022-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥158.2bn	2020-01-21 → 2021-01-20^d	Cons.	Net sales (5-year summary)
Operating income	¥4.8bn	2024-01-21 → 2025-01-20	Cons.	Operating income
Operating income	¥3.7bn	2023-01-21 → 2024-01-20	Cons.	Operating income
Ordinary income	¥3.0bn	2024-01-21 → 2025-01-20	Cons.	Ordinary income
Ordinary income	¥3.1bn	2023-01-21 → 2024-01-20	Cons.	Ordinary income
Ordinary income	¥591m	2022-01-21 → 2023-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2021-01-21 → 2022-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2020-01-21 → 2021-01-20^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	¥7.9bn	2024-01-21 → 2025-01-20	Cons.	Income before income taxes
Profit before tax	¥5.6bn	2023-01-21 → 2024-01-20	Cons.	Income before income taxes
Net income (owners)	¥3.8bn	2024-01-21 → 2025-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	¥4.4bn	2023-01-21 → 2024-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥507m	2022-01-21 → 2023-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥4.0bn	2021-01-21 → 2022-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥3.2bn	2020-01-21 → 2021-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	¥3.4bn	2024-01-21 → 2025-01-20	Cons.	Profit loss
Net income	¥4.6bn	2023-01-21 → 2024-01-20	Cons.	Profit loss
Total assets	¥185.2bn	at 2025-01-20	Cons.	Assets
Total assets	¥177.6bn	at 2024-01-20	Cons.	Assets
Total assets	¥164.2bn	at 2023-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥159.0bn	at 2022-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥157.6bn	at 2021-01-20^d	Cons.	Total assets (5-year summary)
Total liabilities	¥91.7bn	at 2025-01-20	Cons.	Liabilities
Total liabilities	¥86.1bn	at 2024-01-20	Cons.	Liabilities
Net assets / equity	¥93.5bn	at 2025-01-20	Cons.	Net assets
Net assets / equity	¥91.5bn	at 2024-01-20	Cons.	Net assets
Net assets / equity	¥84.1bn	at 2023-01-20^d	Cons.	Net assets
Net assets / equity	¥83.3bn	at 2022-01-20^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥82.6bn	at 2021-01-20^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥30.7bn	at 2025-01-20	Cons.	Cash and deposits
Cash and deposits	¥32.4bn	at 2024-01-20	Cons.	Cash and deposits
Cash & equivalents	¥29.6bn	at 2025-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥33.7bn	at 2024-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥29.2bn	at 2023-01-20^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥30.1bn	at 2022-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥32.7bn	at 2021-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	¥10.8bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥9.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥5.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥8.1bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥12.5bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥11.6bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥1.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥5.0bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥6.5bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥7.6bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	−¥1.7bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥3.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥1.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥3.7bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥2.3bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥120.66	2024-01-21 → 2025-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥140.77	2023-01-21 → 2024-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-16.2	2022-01-21 → 2023-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥127.1	2021-01-21 → 2022-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥100.66	2020-01-21 → 2021-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
Net assets per share	¥2,908.51	at 2025-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,843.99	at 2024-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,663.79	at 2023-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,645.36	at 2022-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,612.23	at 2021-01-20^d	Cons.	Net assets per share (5-year summary)
Equity ratio	49.6%	at 2025-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.4%	at 2024-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.9%	at 2023-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	52.1%	at 2022-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	51.8%	at 2021-01-20^d	Cons.	Equity to asset ratio (5-year summary)
ROE	4.2%	2024-01-21 → 2025-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	5.1%	2023-01-21 → 2024-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	-0.6%	2022-01-21 → 2023-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	4.8%	2021-01-21 → 2022-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	3.8%	2020-01-21 → 2021-01-20^d	Cons.	Rate of return on equity (5-year summary)
Employees	5,555	at 2025-01-20	Cons.	Number of employees
Employees	5,182	at 2024-01-20	Cons.	Number of employees
Employees	4,122	at 2023-01-20^d	Cons.	Number of employees
Employees	4,029	at 2022-01-20^d	Cons.	Number of employees
Employees	3,922	at 2021-01-20^d	Cons.	Number of employees
Revenue	¥5.4bn	2024-01-21 → 2025-01-20	Standalone	Operating revenue1
Revenue	¥5.3bn	2023-01-21 → 2024-01-20	Standalone	Operating revenue1
Revenue	¥5.0bn	2022-01-21 → 2023-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2021-01-21 → 2022-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2020-01-21 → 2021-01-20^d	Standalone	Operating revenue1 (5-year summary)
Operating income	¥972m	2024-01-21 → 2025-01-20	Standalone	Operating income
Operating income	¥1.1bn	2023-01-21 → 2024-01-20	Standalone	Operating income
Ordinary income	¥1.4bn	2024-01-21 → 2025-01-20	Standalone	Ordinary income
Ordinary income	¥2.0bn	2023-01-21 → 2024-01-20	Standalone	Ordinary income
Ordinary income	¥2.3bn	2022-01-21 → 2023-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥2.4bn	2021-01-21 → 2022-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥1.9bn	2020-01-21 → 2021-01-20^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	¥4.2bn	2024-01-21 → 2025-01-20	Standalone	Income before income taxes
Profit before tax	¥4.0bn	2023-01-21 → 2024-01-20	Standalone	Income before income taxes
Net income	¥3.1bn	2024-01-21 → 2025-01-20	Standalone	Profit loss
Net income	¥2.9bn	2023-01-21 → 2024-01-20	Standalone	Profit loss
Net income	¥1.9bn	2022-01-21 → 2023-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥1.4bn	2021-01-21 → 2022-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥899m	2020-01-21 → 2021-01-20^d	Standalone	Net income loss (5-year summary)
Total assets	¥126.0bn	at 2025-01-20	Standalone	Assets
Total assets	¥124.8bn	at 2024-01-20	Standalone	Assets
Total assets	¥122.7bn	at 2023-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥122.2bn	at 2022-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥116.8bn	at 2021-01-20^d	Standalone	Total assets (5-year summary)
Total liabilities	¥43.3bn	at 2025-01-20	Standalone	Liabilities
Total liabilities	¥42.4bn	at 2024-01-20	Standalone	Liabilities
Net assets / equity	¥82.6bn	at 2025-01-20	Standalone	Net assets
Net assets / equity	¥82.4bn	at 2024-01-20	Standalone	Net assets
Net assets / equity	¥80.5bn	at 2023-01-20^d	Standalone	Net assets
Net assets / equity	¥80.1bn	at 2022-01-20^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥78.5bn	at 2021-01-20^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥21.7bn	at 2025-01-20	Standalone	Cash and deposits
Cash and deposits	¥25.8bn	at 2024-01-20	Standalone	Cash and deposits
EPS (basic)	¥98.35	2024-01-21 → 2025-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥92.22	2023-01-21 → 2024-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥61.07	2022-01-21 → 2023-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥45.88	2021-01-21 → 2022-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥28.25	2020-01-21 → 2021-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
Dividend per share	¥40	2024-01-21 → 2025-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2023-01-21 → 2024-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2022-01-21 → 2023-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2021-01-21 → 2022-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2020-01-21 → 2021-01-20^d	Standalone	Dividend paid per share (5-year summary)
Net assets per share	¥2,614.69	at 2025-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,618.07	at 2024-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,564.03	at 2023-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,559.09	at 2022-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,512.97	at 2021-01-20^d	Standalone	Net assets per share (5-year summary)
Equity ratio	65.6%	at 2025-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	66.0%	at 2024-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2023-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2022-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	67.2%	at 2021-01-20^d	Standalone	Equity to asset ratio (5-year summary)
ROE	3.8%	2024-01-21 → 2025-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	3.6%	2023-01-21 → 2024-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	2.4%	2022-01-21 → 2023-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.8%	2021-01-21 → 2022-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.1%	2020-01-21 → 2021-01-20^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	33,137,000	at 2025-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2024-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2023-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2022-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2021-01-20^d	Standalone	Total number of issued shares (5-year summary)
Employees	51	at 2025-01-20	Standalone	Number of employees
Employees	39	at 2024-01-20	Standalone	Number of employees
Employees	26	at 2023-01-20^d	Standalone	Number of employees
Employees	23	at 2022-01-20^d	Standalone	Number of employees
Employees	19	at 2021-01-20^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 95

Segment	Item	Period	Value
Reconciling Itemsreconciling	capex	2024-01-21 → 2025-01-20	¥597m
Reconciling Itemsreconciling	depreciation	2024-01-21 → 2025-01-20	¥796m
Reconciling Itemsreconciling	revenue	2024-01-21 → 2025-01-20	−¥378m
Reconciling Itemsreconciling	revenue intersegment	2024-01-21 → 2025-01-20	−¥378m
Reconciling Itemsreconciling	segment assets	at 2025-01-20	¥34.5bn
Reconciling Itemsreconciling	segment profit	2024-01-21 → 2025-01-20	−¥2.1bn
Domestic Beverage Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥7.1bn
Domestic Beverage Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥5.6bn
Domestic Beverage Businessreportable segment	employees	at 2025-01-20	3676 pure
Domestic Beverage Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥147.5bn
Domestic Beverage Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥147.4bn
Domestic Beverage Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥86m
Domestic Beverage Businessreportable segment	segment assets	at 2025-01-20	¥74.8bn
Domestic Beverage Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥986m
Dy Do Pharmareportable segment	capex	2024-01-21 → 2025-01-20	¥382m
Dy Do Pharmareportable segment	depreciation	2024-01-21 → 2025-01-20	¥21m
Dy Do Pharmareportable segment	employees	at 2025-01-20	12 pure
Dy Do Pharmareportable segment	revenue	2024-01-21 → 2025-01-20	¥8m
Dy Do Pharmareportable segment	revenue external	2024-01-21 → 2025-01-20	¥8m
Dy Do Pharmareportable segment	segment assets	at 2025-01-20	¥780m
Dy Do Pharmareportable segment	segment profit	2024-01-21 → 2025-01-20	−¥621m
Food Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥1.2bn
Food Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥834m
Food Businessreportable segment	employees	at 2025-01-20	309 pure
Food Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥20.6bn
Food Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥7m
Food Businessreportable segment	segment assets	at 2025-01-20	¥21.0bn
Food Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥1.2bn
International Beverage Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥9.0bn
International Beverage Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥1.9bn
International Beverage Businessreportable segment	employees	at 2025-01-20	1148 pure
International Beverage Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥56.3bn
International Beverage Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥56.3bn
International Beverage Businessreportable segment	segment assets	at 2025-01-20	¥37.5bn
International Beverage Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥5.1bn
Pharmaceutical Related Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥576m
Pharmaceutical Related Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥1.4bn
Pharmaceutical Related Businessreportable segment	employees	at 2025-01-20	359 pure
Pharmaceutical Related Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥13.1bn
Pharmaceutical Related Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥12.8bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥284m
Pharmaceutical Related Businessreportable segment	segment assets	at 2025-01-20	¥16.6bn
Pharmaceutical Related Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥277m
—segment total	capex	2024-01-21 → 2025-01-20	¥18.2bn
—segment total	depreciation	2024-01-21 → 2025-01-20	¥9.7bn
—segment total	revenue	2024-01-21 → 2025-01-20	¥237.6bn
—segment total	revenue external	2024-01-21 → 2025-01-20	¥237.2bn
—segment total	revenue intersegment	2024-01-21 → 2025-01-20	¥378m
—segment total	segment assets	at 2025-01-20	¥150.8bn
—segment total	segment profit	2024-01-21 → 2025-01-20	¥6.9bn
Reconciling Itemsreconciling	capex	2023-01-21 → 2024-01-20	¥926m
Reconciling Itemsreconciling	depreciation	2023-01-21 → 2024-01-20	¥793m
Reconciling Itemsreconciling	revenue	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	revenue intersegment	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	segment assets	at 2024-01-20	¥44.8bn
Reconciling Itemsreconciling	segment profit	2023-01-21 → 2024-01-20	−¥2.2bn
Domestic Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥9.4bn
Domestic Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥5.1bn
Domestic Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥26m
Domestic Beverage Businessreportable segment	segment assets	at 2024-01-20	¥74.7bn
Domestic Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥4.3bn
Dy Do Pharmareportable segment	capex	2023-01-21 → 2024-01-20	¥57m
Dy Do Pharmareportable segment	depreciation	2023-01-21 → 2024-01-20	¥9m
Dy Do Pharmareportable segment	segment assets	at 2024-01-20	¥381m
Dy Do Pharmareportable segment	segment profit	2023-01-21 → 2024-01-20	−¥796m
Food Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥638m
Food Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥848m
Food Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥7m
Food Businessreportable segment	segment assets	at 2024-01-20	¥21.4bn
Food Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥993m
International Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥1.2bn
International Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥859m
International Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	segment assets	at 2024-01-20	¥16.7bn
International Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥483m
Pharmaceutical Related Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥13.0bn
Pharmaceutical Related Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥12.6bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥331m
Pharmaceutical Related Businessreportable segment	segment assets	at 2024-01-20	¥19.5bn
Pharmaceutical Related Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥367m
—segment total	capex	2023-01-21 → 2024-01-20	¥11.7bn
—segment total	depreciation	2023-01-21 → 2024-01-20	¥8.0bn
—segment total	revenue	2023-01-21 → 2024-01-20	¥213.7bn
—segment total	revenue external	2023-01-21 → 2024-01-20	¥213.4bn
—segment total	revenue intersegment	2023-01-21 → 2024-01-20	¥366m
—segment total	segment assets	at 2024-01-20	¥132.7bn
—segment total	segment profit	2023-01-21 → 2024-01-20	¥5.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,765

Item	Context	Value
Name of shareholder treasury shares etc	CurrentYearInstant_Row2Member	Original text (Japanese) 株式会社秋田ダイドー
Address of shareholder treasury shares etc	CurrentYearInstant_Row2Member	Original text (Japanese) 秋田県秋田市御野場二丁目1番7号
Share ownership plans for directors and other officers and employees (text)	FilingDateInstant	Text · Plus
Classes of shares etc (text)	FilingDateInstant	Text · Plus
Acquisitions by resolution of shareholders meeting (text)	FilingDateInstant	Text · Plus
Acquisitions by resolution of board of directors meeting (text)	FilingDateInstant	Text · Plus
Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text)	FilingDateInstant	Text · Plus
Disposals or holding of acquired treasury shares (text)	FilingDateInstant	Text · Plus
Dividend policy (text)	FilingDateInstant	Text · Plus
Date of resolution dividends of surplus	FilingDateInstant_Row1Member	2024-08-27
Resolution dividends of surplus	FilingDateInstant_Row1Member	Original text (Japanese) 取締役会決議
Date of resolution dividends of surplus	FilingDateInstant_Row2Member	2025-04-15
Resolution dividends of surplus	FilingDateInstant_Row2Member	Original text (Japanese) 定時株主総会決議
Overview of corporate governance (text)	FilingDateInstant	Text · Plus
Corporate governance company with corporate auditors (text)	FilingDateInstant	Text · Plus
Basic policy regarding control of company (text)	FilingDateInstant	Text · Plus
Information about officers (text)	FilingDateInstant	Text · Plus
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	Original text (Japanese) 代表取締役社長
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	Original text (Japanese) 髙松　富也
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	1976-06-26
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember	Original text (Japanese) 取締役執行役員財務部長
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember	Original text (Japanese) 殿勝　直樹
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember	1963-11-04
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember	Original text (Japanese) 取締役経営戦略・内部統制担当役員
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember	Original text (Japanese) 西山　直行
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember	1965-07-30
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember	Original text (Japanese) 取締役
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember	Original text (Japanese) 井上　正隆
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember	1954-10-12
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember	Original text (Japanese) 取締役
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember	Original text (Japanese) 栗原　道明
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember	1953-10-01
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember	Original text (Japanese) 取締役
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember	Original text (Japanese) 河野　純子（現姓：山内）
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember	1963-09-30
Career summary information about directors and corporate auditors (text)	FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember	Text · Plus
Term of office information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember	＊1
Official title or position information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000ItoMinaMember	Original text (Japanese) 取締役
Name information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000ItoMinaMember	Original text (Japanese) 伊藤　三奈
Date of birth information about directors and corporate auditors	FilingDateInstant_jpcrp030000-asr_E00424-000ItoMinaMember	1967-03-02

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2024-01-20	pass rounding
balance sheet identity	consolidated 2025-01-20	pass rounding
balance sheet identity	non_consolidated 2024-01-20	pass rounding
balance sheet identity	non_consolidated 2025-01-20	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2023-01-20	pass
statement vs summary · net assets	consolidated 2024-01-20	pass
statement vs summary · net assets	consolidated 2025-01-20	pass
statement vs summary · net assets	non_consolidated 2023-01-20	pass
statement vs summary · net assets	non_consolidated 2024-01-20	pass
statement vs summary · net assets	non_consolidated 2025-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · operating cash flow	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · operating cash flow	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · revenue	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · revenue	non_consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	non_consolidated 2024-01-21/2025-01-20	pass
statement vs summary · total assets	consolidated 2024-01-20	pass
statement vs summary · total assets	consolidated 2025-01-20	pass
statement vs summary · total assets	non_consolidated 2024-01-20	pass
statement vs summary · total assets	non_consolidated 2025-01-20	pass